The effect of metformin on Ki-67 change between biopsy
and surgical samples was investigated in a window-of-opportunity
randomized study including 200 nondiabetic operable
breast cancer patients. Ki-67 was not significantly affected by
metformin treatment compared with placebo in the overall
population, whereas a trend toward Ki-67 decrease was observed
in patients with insulin resistance and high body mass